/biz/ - Business & Finance

Antisense Therapeutics. ANP on the ASX, ATHJF on the Pink Sheets, or AWY on the Frankfurt Exchange.

ANP is about to begin a Phase IIB trial in Duchenne Muscular Dystrophy. Their Phase IIA trial showed an INCREASE in PUL 2.0 scores and a DECREASE in fat fraction percentages in muscles. These results are unheard of in DMD.

ANP has received orphan drug designation from both the FDA and EMA. ANP has also recieved RPDD from the FDA, which could turn into a priority review voucher worth $100 million in the future.

ANP's ATL1102 has also been shown to reduce active brain lesions in relapsing remitting multuple sclerosis vs placebo. ATL1102 targets CD49d, which is an inflammatory biomarker. Inflammation is the next hot spot in the biotech and pharma space.

Early results are promising. This could be the opportunity to get on the ground floor of a biotech company that is on the verge of starting an important Phase IIB trial to treat one of the most tragic and debilitating diseases on the face of the planet.